NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine
NovaSil clay intervention in Ghanaians at high risk for aflatoxicosis: II. Reduction in biomarkers of aflatoxin exposure in blood and urine
复制标题
DOI：
10.1080/02652030701598694
复制
发表时间：
2008-05-01
影响因子：
2.9
通讯作者：
Phillips, T. D.
中科院分区：
文献类型：
--
作者：
Wang, P.;Afriyie-Gyawu, E.;Phillips, T. D.
在加纳进行的为期3个月的IIa期临床干预试验中，研究人员对656份血液样本和624份尿液样本进行了NovaSil粘土（NS）降低黄曲霉毒素（AF）生物标志物暴露的效果进行了评估。NS通过胶囊在餐前给药。用放射免疫法测定血清AFM(1) -白蛋白加合物，用免疫亲和-高效液相色谱(HPLC) -荧光法测定尿液AFM(1)代谢物。在基线和1个月时收集的血清样本中，安慰剂组（PL）、低剂量组（LD, 1.5g NS d(-1)）和高剂量组（HD, 3.0g NS d(-1)）的AFB(1)-白蛋白加合物水平相似（p=0.2354和p=0.3645）。然而，与PL组相比，3个月时LD组和HD组的AFB(1)-白蛋白加合物水平均显著降低（p < 0.000 1）。在基线和1个月时收集的尿液样本中AFM(1)的水平在三个研究组之间没有统计学差异。然而，与PL组的中位水平相比，HD组在3个月时收集的样本中AFM(1)的中位水平显著下降（高达58%）（p < 0）。039(1)。此外，与血清AFM(1) -白蛋白加合物的剂量、时间和剂量-时间相互作用以及与尿AFM(1)代谢物的剂量-时间相互作用均有显著影响。结果表明，含有NS粘土的胶囊可以通过减少AF特异性生物标志物来有效降低饲粮AF的生物利用度。
The efficacy of NovaSil clay (NS) to reduce aflatoxin (AF) biomarkers of exposure was evaluated in 656 blood samples and 624 urine samples collected from study participants during a 3-month phase IIa clinical intervention trial in Ghana. NS was delivered before meals via capsules. Serum AFB(1)-albumin adduct was measured by radioimmunoassay and urinary AFM(1) metabolites were quantified by immunoaffinity-high-performance liquid chromatography (HPLC) -fluorescence methods. Levels of AFB(1)-albumin adduct in serum samples collected at baseline and at I month were similar (p=0.2354 and p=0.3645, respectively) among the placebo (PL), low dose (LD, 1.5g NS day(-1)), and high dose (HD, 3.0g NS day(-1)) groups. However, the levels of AFB(1)-albumin adduct at 3 months were significantly decreased in both the LD group (p < 0.000 1) and the HD group (p < 0.000 1) compared with levels in the PL group. Levels of AFM(1) in urine samples collected at baseline and at 1 month were not statistically different among the three study groups. However, a significant decrease (up to 58%) in the median level of AFM(1) in samples collected at 3 months was found in the HD group when compared with the median level in the PL group (p < 0. 039 1). In addition, significant effects were found for dose, time, and dose-time interaction with serum AFB(1)-albumin adduct and dose-time interaction with urinary AFM(1) metabolites. The results suggest that capsules containing NS clay can be used to reduce effectively the bioavailability of dietary AF based on a reduction of AF-specific biomarkers.